Our director Sarah Acaster led a study team to develop the first cystic fibrosis disease specific preference-based scoring algorithm based on the Cystic Fibrosis Quality of Life – Revised Questionnaire (CFQ-R). If you’re at the North American Cystic Fibrosis Conference (NACFC) this week you can be the first to see the results of this work in Poster Session 1, tomorrow at 11:15 – 1:45: ‘Development of the CFQ-R preference-based scoring algorithm’.
Our director Andrew Lloyd and research associate Natalia Piglowska recently co-authored a paper entitled ‘Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy’ in the British Journal of Ophthalmology.
We are pleased to announce that our director Andrew Lloyd was co-author on a poster entitled ‘Can the EQ-5D capture health outcomes in degenerative rare diseases? An international study’ which received the Lee B Lusted award for Patient and Stakeholder Preferences at the Society for Medical Decision Making last week. Please contact us if you would like a copy of the poster.
The Acaster Lloyd Consulting team will be at ISOQOL in San Diego from 20th to 23rd October. Please get in touch with Sarah Acaster (email@example.com) or Kate Williams (firstname.lastname@example.org) if you’d like to set up a meeting, or come to one of our presentations:
Sarah Acaster: ‘Health-related quality of life associated with Hamilton Rating Scale for Depression remission and response in postpartum depression’
Kate Williams: ‘The Rett Syndrome Burden of Illness Survey: Results from Cognitive Debriefing Interviews’
Kate Williams will be giving a talk entitled ‘Engagement with caregivers during the development and implementation of a survey to evaluate the impact of a rare neurodevelopmental disorder’ as part of Symposium 6 on Wednesday 23rd October at 8.30am-9.45am.
Our team, including Director Sarah Acaster and Senior Research Manager Katy Gallop recently conducted a large European study exploring the psychosocial impact of living with peanut allergy. The results relating to Germany and the UK will be presented in the following upcoming conferences: “APPEAL (Allergy to Peanuts ImPacting Emotions and Life) 1 and 2: Results on Peanut Allergy Impact on Allergic Individuals, Parents and Caregivers in Germany” will be presented as an eposter on Friday 27th September. The UK results will be presented in the poster session at BSACI on Friday 4th October.
The Acaster Lloyd Consulting XLH Team, consisting of Andrew Lloyd, Siu Hing Lo and Natalia Piglowska, recently completed a multi-country study exploring the disease burden of X-linked hypophosphatemia (XLH) among adults. Results will be presented at the ASBMR in a poster session on Sunday 22 September at 12.30-2.30PM in the West Hall C/Orange County Convention Center. Look out for “Exploring the Burden Of X-Linked Hypophosphatemia: A European Multi-Country Qualitative Study [SUN-699]”.
This new paper by our Director, Sarah Acaster, reports on a novel biomarker in celiac disease, which unlike existing biomarkers used in this disease area is correlated with patient reported symptoms, and demonstrates the nature and time course of symptom change in the hours following gluten ingestion.
Our team, including Director Sarah Acaster and Senior Research Manager Katy Gallop recently conducted a large European qualitative study exploring the psychosocial impact of living with peanut allergy on adults, adolescents, children and caregivers. If you’re going to EAACI you can view the poster of results “Allergy to Peanut ImPacting Emotions And Life (APPEAL) 2: The first European multi-country qualitative evaluation of the impact of living with peanut allergy” in the Late-Breaking Poster Discussion Session on Monday 3rd June.
Acaster Lloyd Consulting, in a team led by director Sarah Acaster, have had the pleasure of working with Sage Therapeutics during their achievement of the first FDA approved treatment for postpartum depression. A fantastic result for the women and their families in this critical population. As part of this work stream, in an effort to relate patient-reported and clinician-reported outcomes, our director, Sarah Acaster, was part of a study team to explore the relationship between the Hamilton Depression Rating Scale (HAM-D) and Edinburgh Post Natal Depression Scale (EPDS). If you’re going to APA next week you can view the related poster: ‘The association between the HAM-D and EPDS in postpartum depression’ in the poster session on Tuesday 21st May ref: P7-092.
Look out for news of further dissemination associated with this work.